264 related articles for article (PubMed ID: 32930144)
21. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
[TBL] [Abstract][Full Text] [Related]
22. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI.
Yi HG; Kim HJ; Kim YJ; Han SW; Oh DY; Lee SH; Kim DW; Im SA; Kim TY; Kim CS; Heo DS; Bang YJ
Lung Cancer; 2009 Jul; 65(1):80-4. PubMed ID: 19059670
[TBL] [Abstract][Full Text] [Related]
23. Bevacizumab and gefitinib enhanced whole-brain radiation therapy for brain metastases due to non-small-cell lung cancer.
Yang RF; Yu B; Zhang RQ; Wang XH; Li C; Wang P; Zhang Y; Han B; Gao XX; Zhang L; Jiang ZM
Braz J Med Biol Res; 2017 Nov; 51(1):e6073. PubMed ID: 29185589
[TBL] [Abstract][Full Text] [Related]
24. Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era.
Park JH; Kim YJ; Lee JO; Lee KW; Kim JH; Bang SM; Chung JH; Kim JS; Lee JS
Lung Cancer; 2012 Jun; 76(3):387-92. PubMed ID: 22186628
[TBL] [Abstract][Full Text] [Related]
25. Gefitinib with or without Transarterial Infusion Chemotherapy (Cisplatin) for Large Nonsmall Cell Lung Cancer with Epidermal Growth Factor Receptor Mutations.
Zhang YQ; Jiang LJ; Jiang SX; Xu YF; Zhou BB; Huang GH; Liu DM; Wang Y; Fan WZ; Li JP; Wang B
J Vasc Interv Radiol; 2019 Jul; 30(7):1004-1012. PubMed ID: 31171399
[TBL] [Abstract][Full Text] [Related]
26. [Epidermal growth factor tyrosine kinase inhibitors used in the treatment of NSCLC patients with leptomeningeal metastasis].
Xu Y; Zhong W; Zhao J; Chen MJ; Zhang L; Li LY; Wang MZ
Zhonghua Zhong Liu Za Zhi; 2016 Dec; 38(12):920-924. PubMed ID: 27998469
[No Abstract] [Full Text] [Related]
27. A review of whole brain radiotherapy outcomes in a high epidermal growth factor receptor mutation rate population: Does QUARTZ apply in Asia?
Ng IW; Tey JCS; Chia DWT; Yee CM; Cheo TST
Asia Pac J Clin Oncol; 2019 Dec; 15(6):353-357. PubMed ID: 31267659
[TBL] [Abstract][Full Text] [Related]
28. The rate of occurrence, healthcare resource use and costs of adverse events among metastatic non-small cell lung cancer patients treated with first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors.
Subramanian J; Fernandes AW; Laliberté F; Pavilack M; DerSarkissian M; Duh MS
Lung Cancer; 2019 Dec; 138():131-138. PubMed ID: 31733614
[TBL] [Abstract][Full Text] [Related]
29. Great efficacy of bevacizumab plus erlotinib for leptomeningeal metastases from non-small cell lung cancer with initially positive EGFR mutation: a case report.
Jing W; Wang H; Kong L; Yu J; Zhu H
Cancer Biol Ther; 2018; 19(12):1073-1077. PubMed ID: 30067451
[TBL] [Abstract][Full Text] [Related]
30. Successful treatment using targeted therapy, radiotherapy, and intrathecal chemotherapy in a patient with leptomeningeal metastasis with an epidermal growth factor receptor exon 20 insertion mutation: a case report.
Ma Y; Liu H; Zhang M; Liu B; Ding Q; Zhang L; Guo L; Liu M
Ann Palliat Med; 2022 Apr; 11(4):1533-1541. PubMed ID: 34263612
[TBL] [Abstract][Full Text] [Related]
31. Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in
Noronha V; Patil VM; Joshi A; Menon N; Chougule A; Mahajan A; Janu A; Purandare N; Kumar R; More S; Goud S; Kadam N; Daware N; Bhattacharjee A; Shah S; Yadav A; Trivedi V; Behel V; Dutt A; Banavali SD; Prabhash K
J Clin Oncol; 2020 Jan; 38(2):124-136. PubMed ID: 31411950
[TBL] [Abstract][Full Text] [Related]
32. Retrospective analysis of survival in patients with leptomeningeal carcinomatosis from lung adenocarcinoma treated with erlotinib and gefitinib.
Kashima J; Okuma Y; Miwa M; Hosomi Y
Jpn J Clin Oncol; 2017 Apr; 47(4):357-362. PubMed ID: 28064206
[TBL] [Abstract][Full Text] [Related]
33. A prospective, multicenter phase II trial of low-dose erlotinib as maintenance treatment after platinum doublet chemotherapy for advanced non-small cell lung cancer harboring EGFR mutation.
Hirano S; Naka G; Takeda Y; Iikura M; Hayama N; Yanagisawa A; Amano H; Nakamura M; Nakamura S; Tabeta H; Sugiyama H
Chin Clin Oncol; 2016 Dec; 5(6):77. PubMed ID: 28061541
[TBL] [Abstract][Full Text] [Related]
34. Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902.
Sugawara S; Oizumi S; Minato K; Harada T; Inoue A; Fujita Y; Maemondo M; Yoshizawa H; Ito K; Gemma A; Nishitsuji M; Harada M; Isobe H; Kinoshita I; Morita S; Kobayashi K; Hagiwara K; Kurihara M; Nukiwa T
Ann Oncol; 2015 May; 26(5):888-894. PubMed ID: 25669832
[TBL] [Abstract][Full Text] [Related]
35. High-dose erlotinib for refractory leptomeningeal metastases after failure of standard-dose EGFR-TKIs.
Kawamura T; Hata A; Takeshita J; Fujita S; Hayashi M; Tomii K; Katakami N
Cancer Chemother Pharmacol; 2015 Jun; 75(6):1261-6. PubMed ID: 25921002
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of intrathecal pemetrexed for TKI-failed leptomeningeal metastases from EGFR+ NSCLC: an expanded, single-arm, phase II clinical trial.
Fan C; Jiang Z; Teng C; Song X; Li L; Shen W; Jiang Q; Huang D; Lv Y; Du L; Wang G; Hu Y; Man S; Zhang Z; Gao N; Wang F; Shi T; Xin T
ESMO Open; 2024 Apr; 9(4):102384. PubMed ID: 38377785
[TBL] [Abstract][Full Text] [Related]
37. An Acquired Epidermal Growth Factor Receptor T790M Mutation after the Addition of Bevacizumab to Preceding Erlotinib Monotherapy in a Lung Cancer Patient with Leptomeningeal Metastases.
Tsuchiya K; Karayama M; Yasui H; Hozumi H; Suzuki Y; Furuhashi K; Enomoto N; Fujisawa T; Nakamura Y; Inui N; Suda T
Intern Med; 2018 Dec; 57(23):3423-3427. PubMed ID: 30101917
[TBL] [Abstract][Full Text] [Related]
38. Gefitinib alone or with concomitant whole brain radiotherapy for patients with brain metastasis from non-small-cell lung cancer: a retrospective study.
Zeng YD; Zhang L; Liao H; Liang Y; Xu F; Liu JL; Dinglin XX; Chen LK
Asian Pac J Cancer Prev; 2012; 13(3):909-14. PubMed ID: 22631670
[TBL] [Abstract][Full Text] [Related]
39. Pemetrexed in the Treatment of Leptomeningeal Metastasis in Patients With EGFR-mutant Lung Cancer.
Choi M; Keam B; Ock CY; Kim M; Kim TM; Kim DW; Heo DS
Clin Lung Cancer; 2019 Jul; 20(4):e442-e451. PubMed ID: 31010639
[TBL] [Abstract][Full Text] [Related]
40. Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study.
Chen YH; Chen YF; Chen CY; Shih JY; Yu CJ
BMC Cancer; 2019 Oct; 19(1):1006. PubMed ID: 31655564
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]